ALB and acute myeloid leukemia: Only two anticancer nanoparticles are used as front-line therapies: nanoparticle albumin-bound paclitaxel (nab-paclitaxel; Abraxane) is approved for first-line treatment of advanced non-small cell lung cancer and metastatic pancreatic adenocarcinoma, and liposomal daunorubicin cytarabine (CPX-351; Vyxeos), the only dual drug nanoparticle on the market, is approved for newly diagnosed treatment-related acute myeloid leukemia and acute myeloid leukemia with myelodysplastic changes.